• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
[Retracted] miR‑222 regulates sorafenib resistance and enhance tumorigenicity in hepatocellular carcinoma.[已撤回] miR-222调节肝癌中索拉非尼耐药性并增强致瘤性。
Int J Oncol. 2021 Dec;59(6). doi: 10.3892/ijo.2021.5280. Epub 2021 Nov 2.
2
[Retracted] miR‑494 promotes cell proliferation, migration and invasion, and increased sorafenib resistance in hepatocellular carcinoma by targeting PTEN.[已撤回] miR-494通过靶向PTEN促进肝癌细胞增殖、迁移和侵袭,并增加对索拉非尼的耐药性。
Oncol Rep. 2022 Feb;47(2). doi: 10.3892/or.2021.8236. Epub 2021 Dec 1.
3
[Retracted] MiR‑132 inhibits cell proliferation, invasion and migration of hepatocellular carcinoma by targeting PIK3R3.[已撤回] miR-132通过靶向PIK3R3抑制肝癌细胞的增殖、侵袭和迁移。
Int J Oncol. 2021 Aug;59(2). doi: 10.3892/ijo.2021.5238. Epub 2021 Jul 1.
4
[Retracted] Synergistic growth inhibition by sorafenib and cisplatin in human osteosarcoma cells.[已撤回] 索拉非尼和顺铂对人骨肉瘤细胞的协同生长抑制作用。
Oncol Rep. 2021 Sep;46(3). doi: 10.3892/or.2021.8144. Epub 2021 Jul 19.
5
[Retracted] miR‑154 targeting ZEB2 in hepatocellular carcinoma functions as a potential tumor suppressor.[已撤回] 肝细胞癌中靶向ZEB2的miR-154发挥潜在肿瘤抑制作用。
Oncol Rep. 2021 Aug;46(2). doi: 10.3892/or.2021.8113. Epub 2021 Jun 16.
6
[Retracted] Silencing XIAP suppresses osteosarcoma cell growth, and enhances the sensitivity of osteosarcoma cells to doxorubicin and cisplatin.[已撤回] 沉默X连锁凋亡抑制蛋白可抑制骨肉瘤细胞生长,并增强骨肉瘤细胞对阿霉素和顺铂的敏感性。
Oncol Rep. 2022 Jan;47(1). doi: 10.3892/or.2021.8213. Epub 2021 Nov 2.
7
[Retracted] miR‑338‑3p suppresses tumor growth of ovarian epithelial carcinoma by targeting Runx2.[已撤回] miR-338-3p通过靶向Runx2抑制卵巢上皮癌的肿瘤生长。
Int J Oncol. 2021 Aug;59(2). doi: 10.3892/ijo.2021.5237. Epub 2021 Jul 1.
8
[Retracted] MicroRNA‑154 functions as a tumor suppressor in osteosarcoma by targeting Wnt5a.[已撤回] 微小RNA-154通过靶向Wnt5a在骨肉瘤中发挥肿瘤抑制作用。
Oncol Rep. 2021 Aug;46(2). doi: 10.3892/or.2021.8130. Epub 2021 Jul 19.
9
[Retracted] miR-126 inhibits papillary thyroid carcinoma growth by targeting LRP6.[已撤回] miR-126通过靶向LRP6抑制甲状腺乳头状癌生长。
Oncol Rep. 2021 Jul;46(1). doi: 10.3892/or.2021.8097. Epub 2021 Jun 3.
10
[Retracted] miR‑133a inhibits cervical cancer growth by targeting EGFR.[已撤回] miR-133a通过靶向表皮生长因子受体抑制宫颈癌生长。
Oncol Rep. 2021 Jul;46(2). doi: 10.3892/or.2021.8103. Epub 2021 Jun 3.

[已撤回] miR-222调节肝癌中索拉非尼耐药性并增强致瘤性。

[Retracted] miR‑222 regulates sorafenib resistance and enhance tumorigenicity in hepatocellular carcinoma.

作者信息

Liu Kai, Liu Songyang, Zhang Wei, Ji Bai, Wang Yingchao, Liu Yahui

机构信息

Department of Hepatopancreatobiliary Surgery, The First Hospital, Jilin University, Changchun, Jilin Province, P.R. China.

出版信息

Int J Oncol. 2021 Dec;59(6). doi: 10.3892/ijo.2021.5280. Epub 2021 Nov 2.

DOI:10.3892/ijo.2021.5280
PMID:34726253
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8577794/
Abstract

Following the publication of this paper, it was drawn to the Editors' attention by a concerned reader that the flow cytometric data in Fig. 3A and western blotting data featured in Figs. 3C and 7 were strikingly similar to data appearing in different form in other articles that shared some of the same authors. Owing to the fact that the contentious data in the above article were already under consideration for publication, or had already been published, elsewhere prior to its submission to , the Editor has decided that this paper should be retracted from the Journal. After having been in contact with the authors, they agreed with the decision to retract the paper. The Editor apologizes to the readership for any inconvenience caused. [the original article was published in International Journal of Oncology 45: 1537‑1546, 2014; DOI: 10.3892/ijo.2014.2577].

摘要

在本文发表之后,一位关注此事的读者提醒编辑注意,图3A中的流式细胞术数据以及图3C和7中的蛋白质印迹数据与其他一些有部分相同作者的文章中以不同形式出现的数据惊人地相似。由于上述文章中有争议的数据在提交至本期刊之前已在其他地方被考虑发表或已发表,编辑决定将本文从期刊中撤回。在与作者联系后,他们同意撤回该论文的决定。编辑就由此造成的不便向读者表示歉意。[原文发表于《国际肿瘤学杂志》2014年第45卷,第1537 - 1546页;DOI: 10.3892/ijo.2014.2577]